(August 23 06:23) Forbes.com
“With China on board, you have a scale of population and an ability to reach out to patients willing to join trials,” said Dr. Bob Li, a lung cancer specialist at the Memorial Sloan Kettering Cancer Center in New York.
You can find the original article
here